EC Pulmonology and Respiratory Medicine

Transient receptor potential vanilloid 1 (TRPV1) and TRPV2 are prominent members of TRPV group of transient receptor potential family of ion channels. These channels play crucial roles in various physiological processes and are implicated in several illnesses. TRPV1 primarily contributes to itch, inflammation, pain perception, respiratory disorders, eliciting itching sensations, promoting inflammation, and transmitting pain signals. In contrast, TRPV2 is associated with pain, cancer, and neurodegenerative diseases, exhibiting heightened pain sensitivity and sensitization following nerve injury, though its exact role in pain remains incompletely understood. This in-depth review explores the functions of TRPV1 and TRPV2 in diverse array of diseases, such as cancer, neurodegenerative diseases, and respiratory conditions. The review provides insights into their mechanisms of action and the impact of different stimuli on their activation. Furthermore, it explores the potential therapeutic applications of targeting TRPV1 and TRPV2, offering prospects for their utilization in the treatment of pain and related conditions. Insights into ongoing clinical studies investigating TRPV1 and TRPV2 modulators for the treatment of pain and other related conditions are also provided by the review. For the advancement of precision medicine techniques and the development of targeted therapies, it is essential to comprehend the roles of TRPV1 and TRPV2 in diseases.

 Keywords: TRPV1; TRPV2; Disease; Pain Sensation; Inflammation; Therapeutic Targets

1. Zhu ZY., et al. “Activation of transient receptor potential vanilloid 1 inhibits RhoA/Rho kinase and improves vasorelaxation dysfunction mediated by high-fat diet in mice”. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 6 (2011): 600-605.
2. Baylie R and J Brayden. “TRPV channels and vascular function”. Acta Physiologica 1 (2011): 99-116.
3. Pumroy RA., et al. “Molecular mechanism of TRPV2 channel modulation by cannabidiol”. Elife 8 (2019): e48792.
4. Seebohm G and JA Schreiber. “Beyond hot and spicy: TRPV channels and their pharmacological modulation”. Cellular Physiology and Biochemistry S3 (2021): 108-130.
5. Rayees S., et al. “PAR2-mediated cAMP generation suppresses TRPV4-dependent Ca²⁺ signaling in alveolar macrophages to resolve TLR4-induced inflammation”. Cell Reports 3 (2019): 793-805. e4.
6. Rayees S., et al. “Macrophage TLR4 and PAR2 signaling: role in regulating vascular inflammatory injury and repair”. Frontiers in Immunology 11 (2020): 2091.
7. Li L., et al. “The impact of TRPV1 on cancer pathogenesis and therapy: a systematic review”. International Journal of Biological Sciences 8 (2021): 2034.
8. Caterina MJ., et al. “The capsaicin receptor: a heat-activated ion channel in the pain pathway”. Nature6653 (1997): 816-824.
9. Bujak JK., et al. “Inflammation, cancer and immunity-implication of TRPV1 channel”. Frontiers in Oncology 9 (2019): 1087.
10. Koivisto AP., et al. “Advances in TRP channel drug discovery: from target validation to clinical studies”. Nature Reviews Drug Discovery 1 (2022): 41-59.
11. Zubcevic L., et al. “Cryo-electron microscopy structure of the TRPV2 ion channel”. Nature Structural and Molecular Biology 2 (2016): 180-186.
12. Dumitrache MD., et al. “Comparative effects of capsaicin in chronic obstructive pulmonary disease and asthma”. Experimental and Therapeutic Medicine 3 (2021): 1-12.
13. Baker K., et al. “Role of the ion channel, transient receptor potential cation channel subfamily V member 1 (TRPV1), in allergic asthma”. Respiratory Research 17 (2016): 1-10.
14. Rayees S., et al. “Protease-activated receptor 2 promotes clearance of Pseudomonas aeruginosa infection by inducing cAMP-Rac1 signaling in alveolar macrophages”. Frontiers in Pharmacology 13 (2022): 874197.
15. Rayees S., et al. “Linking GATA-3 and interleukin-13: implications in asthma”. Inflammation Research 63 (2014): 255-265.
16. Sommer C and M Kress. “Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia”. Neuroscience Letters 1-3 (2004): 184-187.
17. Masubuchi H., et al. “Reduced transient receptor potential vanilloid 2 expression in alveolar macrophages causes COPD in mice through impaired phagocytic activity”. BMC Pulmonary Medicine 19 (2019): 1-10.
18. Dąbrowiecki P., et al. “Respiratory diseases admissions due to the smog episode in Warsaw in January 2017. 2018”. European Respiratory Society - ERS (2018).
19. Stock K., et al. “Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1”. Nature Medicine 8 (2012): 1232-1238.
20. Hartel M., et al. “Vanilloids in pancreatic cancer: potential for chemotherapy and pain management”. Gut4 (2006): 519-528.
21. Marincsák R., et al. “Increased expression of TRPV1 in squamous cell carcinoma of the human tongue”. Oral Diseases 5 (2009): 328-335.
22. Czifra G., et al. “Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma”. Journal of Cancer Research and Clinical Oncology 135 (2009): 507-514.
23. Weber LV., et al. “Expression and functionality of TRPV1 in breast cancer cells”. Breast Cancer: Targets and Therapy (2016): 243-252.
24. Khan SU., et al. “Targeting redox regulation and autophagy systems in cancer stem cells”. Clinical and Experimental Medicine (2022): 1-19.
25. Nabissi M., et al. “Cannabidiol stimulates A ml‐1a‐dependent glial differentiation and inhibits glioma stem‐like cells proliferation by inducing autophagy in a TRPV 2‐dependent manner”. International Journal of Cancer 8 (2015): 1855-1869.
26. Ivanov VN., et al. “Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways”. Oncotarget43 (2017): 74068.
27. Zhang X., et al. “Cannabidiol induces cell cycle arrest and cell apoptosis in human gastric cancer SGC-7901 cells”. Biomolecules8 (2019): 302.
28. Marinelli O., et al. “The effects of cannabidiol and prognostic role of TRPV2 in human endometrial cancer”. International Journal of Molecular Sciences 15 (2020): 5409.
29. Siveen KS., et al. “Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation”. Scientific Reports1 (2019): 1554.
30. Hong C., et al. “TRP channels as emerging therapeutic targets for neurodegenerative diseases”. Frontiers in Physiology 11 (2020): 238.
31. Lu J., et al. “TRPV1 sustains microglial metabolic reprogramming in Alzheimer's disease”. EMBO Reports 6 (2021): e52013.
32. Bai Y., et al. “Bell's palsy was associated with TRPV2 downregulation of Schwann cell by cold stress”. Journal of Stomatology, Oral and Maxillofacial Surgery (2023): 101533.
33. Katz B., et al. “Nociception and pain in humans lacking a functional TRPV1 channel”. The Journal of Clinical Investigation 3 (2023).
34. Iftinca M., et al. “TRPV1-targeted drugs in development for human pain conditions”. Drugs1 (2021): 7-27.
35. Louis-Gray K., et al. “TRPV1: a common denominator mediating antinociceptive and antiemetic effects of cannabinoids”. International Journal of Molecular Sciences 17 (2022): 10016.
36. Jardín I., et al. “TRPs in pain sensation”. Frontiers in Physiology 8 (2017): 392.
37. Kargbo RB. “TRPV1 Modulators for the Treatment of Pain and Inflammation”. ACS Publications (2019): 143-144.
38. Fernández-Carvajal A., et al. “Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels”. Expert Opinion on Investigational Drugs 11 (2020): 1209-1222.
39. Dietrich A. “Modulators of transient receptor potential (TRP) channels as therapeutic options in lung disease”. Pharmaceuticals1 (2019): 23.
40. Rodrigues T., et al. “Natural product modulators of transient receptor potential (TRP) channels as potential anti-cancer agents”. Chemical Society Reviews 22 (2016): 6130-6137.